Literature DB >> 27666565

Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.

Lauren Johnson1, Mary D Sammel2, Allison Schanne3, Lara Lechtenberg3, Maureen Prewitt3, Clarisa Gracia3.   

Abstract

OBJECTIVE: To evaluate reproductive hormone patterns in women exposed to alkylating-agent chemotherapy.
DESIGN: Prospective cohort.
SETTING: University hospital. PATIENT(S): Normally menstruating mid-reproductive-age women (20-35 years old) who had previously been exposed to alkylating-agent chemotherapy for cancer treatment were compared with two healthy control populations: similarly-aged women and late-reproductive-age women (43-50 years old). INTERVENTION(S): Subjects collected daily urine samples for one cycle. MAIN OUTCOME MEASURE(S): Integrated urinary pregnanediol glucuronide (PDG) and estrone conjugate (E1c) and urinary excretion of gonadotropins (FSH and LH). RESULT(S): Thirty-eight women (13 survivors, 11 same-age control subjects, 14 late-reproductive-age control subjects) provided 1,082 urine samples. Cycle length, luteal phase length, and evidence of luteal activity were similar among the groups. As expected, ovarian reserve was impaired in cancer survivors compared with same-age control subjects but similar between survivors and late-reproductive-age control subjects. In contrast, survivors had total and peak PDG levels that were similar to same-age control subjects and higher than those observed in late-reproductive-age control subjects. Survivors had higher E1c levels than both same-age and late-reproductive-age control subjects. There was no difference in urinary gonadotropins among the groups. CONCLUSION(S): Women exposed to alkylating agents have a unique reproductive hormone milieu that is not solely explained by age or ovarian reserve. The urinary hormone profile observed in survivors appears more similar to same-age control subjects than to late-reproductive-age women with similar ovarian reserve, which may suggest that age plays a more important role than ovarian reserve in the follicular dynamics of survivors.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E1c; PDG; Progesterone excretion; cancer survivors; urinary hormones

Mesh:

Substances:

Year:  2016        PMID: 27666565      PMCID: PMC5136317          DOI: 10.1016/j.fertnstert.2016.08.041

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  25 in total

1.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

2.  Female reproductive aging is marked by decreased secretion of dimeric inhibin.

Authors:  C K Welt; D J McNicholl; A E Taylor; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

3.  Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada.

Authors:  A M Chiarelli; L D Marrett; G Darlington
Journal:  Am J Epidemiol       Date:  1999-08-01       Impact factor: 4.897

4.  Cancer incidence and mortality, 1973-1995: a report card for the U.S.

Authors:  P A Wingo; L A Ries; H M Rosenberg; D S Miller; B K Edwards
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

5.  Follicular phase hormone levels and menstrual bleeding status in the approach to menopause.

Authors:  E W Freeman; M D Sammel; C R Gracia; S Kapoor; H Lin; L Liu; D B Nelson
Journal:  Fertil Steril       Date:  2005-02       Impact factor: 7.329

6.  Factors related to declining luteal function in women during the menopausal transition.

Authors:  N Santoro; S L Crawford; W L Lasley; J L Luborsky; K A Matthews; D McConnell; J F Randolph; E B Gold; G A Greendale; S G Korenman; L Powell; M F Sowers; G Weiss
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

7.  Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer.

Authors:  J Byrne; J J Mulvihill; M H Myers; R R Connelly; M D Naughton; M R Krauss; S C Steinhorn; D D Hassinger; D F Austin; K Bragg
Journal:  N Engl J Med       Date:  1987-11-19       Impact factor: 91.245

8.  Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women.

Authors:  N Santoro; T Adel; J H Skurnick
Journal:  Fertil Steril       Date:  1999-04       Impact factor: 7.329

9.  Characterization of reproductive hormonal dynamics in the perimenopause.

Authors:  N Santoro; J R Brown; T Adel; J H Skurnick
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

10.  Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.

Authors:  Katherine E Dillon; Mary D Sammel; Maureen Prewitt; Jill P Ginsberg; Dana Walker; Jennifer E Mersereau; Yasmin Gosiengfiao; Clarisa R Gracia
Journal:  Fertil Steril       Date:  2012-10-18       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.